127 related articles for article (PubMed ID: 11353634)
1. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): multicenter study of patients treated with RT inhibitors.
Masquelier B; Race E; Tamalet C; Descamps D; Izopet J; Buffet-Janvresse C; Ruffault A; Mohammed AS; Cottalorda J; Schmuck A; Calvez V; Dam E; Fleury H; Brun-Vézinet F;
Antimicrob Agents Chemother; 2001 Jun; 45(6):1836-42. PubMed ID: 11353634
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals.
Balotta C; Berlusconi A; Pan A; Violin M; Riva C; Colombo MC; Gori A; Papagno L; Corvasce S; Mazzucchelli R; Facchi G; Velleca R; Saporetti G; Galli M; Rusconi S; Moroni M
Antivir Ther; 2000 Mar; 5(1):7-14. PubMed ID: 10846586
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
Horban A; Stanczak JJ; Bakowska E; Tobolewska EJ; Przybylska-Stengiel KJ; Stanczak GP; Burkacka E
Infection; 2002 Dec; 30(6):356-9. PubMed ID: 12478325
[TBL] [Abstract][Full Text] [Related]
4. Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Miller V; Larder BA
Antivir Ther; 2001; 6 Suppl 3():25-44. PubMed ID: 11678471
[TBL] [Abstract][Full Text] [Related]
5. In vitro study of resistance-associated genotypic mutations to nucleoside analogs.
Gashnikova N; Plyasunova O; Kiseleva Y; Fedyuk N; Pokrovsky A
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):991-4. PubMed ID: 14565328
[TBL] [Abstract][Full Text] [Related]
6. Drug-resistant reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART.
Caride E; Brindeiro R; Hertogs K; Larder B; Dehertogh P; Machado E; de Sá CA; Eyer-Silva WA; Sion FS; Passioni LF; Menezes JA; Calazans AR; Tanuri A
Virology; 2000 Sep; 275(1):107-15. PubMed ID: 11017792
[TBL] [Abstract][Full Text] [Related]
7. The reverse transcriptase codon 69 insertion is observed in nucleoside reverse transcriptase inhibitor-experienced HIV-1-infected individuals, including those without prior or concurrent zidovudine therapy.
Ross L; Johnson M; Graham N; Shaefer M; St Clair M
J Hum Virol; 1999; 2(5):290-5. PubMed ID: 10551735
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism and drug selected mutations of reverse transcriptase gene in 102 HIV-1 infected patients living in China.
Liu L; Lu HZ; Henry M; Tamalet C
J Med Virol; 2007 Oct; 79(10):1593-9. PubMed ID: 17705165
[TBL] [Abstract][Full Text] [Related]
9. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Picard V; Angelini E; Maillard A; Race E; Clavel F; Chêne G; Ferchal F; Molina JM
J Infect Dis; 2001 Sep; 184(6):781-4. PubMed ID: 11517441
[TBL] [Abstract][Full Text] [Related]
10. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine.
Izopet J; Bicart-See A; Pasquier C; Sandres K; Bonnet E; Marchou B; Puel J; Massip P
J Med Virol; 1999 Dec; 59(4):507-11. PubMed ID: 10534734
[TBL] [Abstract][Full Text] [Related]
11. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
Lanier ER; Givens N; Stone C; Griffin P; Gibb D; Walker S; Tisdale M; Irlbeck D; Underwood M; St Clair M; Ait-Khaled M
HIV Med; 2004 Nov; 5(6):394-9. PubMed ID: 15544690
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Gómez-Cano M; Rubio A; Puig T; Pérez-Olmeda M; Ruiz L; Soriano V; Pineda JA; Zamora L; Xaus N; Clotet B; Leal M
AIDS; 1998 Jun; 12(9):1015-20. PubMed ID: 9662197
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Liu J; Yue J; Wu S; Yan Y
Arch Virol; 2007; 152(10):1799-805. PubMed ID: 17619115
[TBL] [Abstract][Full Text] [Related]
14. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Reinis M; Vandasová J; Stanková M; Linka M; Brůcková M
Acta Virol; 2001; 45(5-6):279-86. PubMed ID: 12083326
[TBL] [Abstract][Full Text] [Related]
16. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine.
Røge BT; Katzenstein TL; Obel N; Nielsen H; Kirk O; Pedersen C; Mathiesen L; Lundgren J; Gerstoft J
Antivir Ther; 2003 Apr; 8(2):173-82. PubMed ID: 12741630
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
18. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcriptase mutations at codons 44 and 118.
Romano L; Venturi G; Bloor S; Harrigan R; Larder BA; Major JC; Zazzi M
J Infect Dis; 2002 Apr; 185(7):898-904. PubMed ID: 11920313
[TBL] [Abstract][Full Text] [Related]
19. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
[TBL] [Abstract][Full Text] [Related]
20. Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Balestre E; Dupon M; Capdepont S; Thiébaut R; Boucher S; Fleury H; Dabis F; Masquelier B;
J Clin Virol; 2006 Jun; 36(2):95-9. PubMed ID: 16556509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
